Segment Information

6 Months Ended

Dec. 27, 2014

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

SEGMENT INFORMATION

The Company has five reportable segments, aligned primarily by type of product: Consumer Healthcare, Nutritionals, Rx Pharmaceuticals, API, and Specialty Sciences, along with an Other category. In conjunction with the Elan acquisition on December 18, 2013, the Company expanded its operating segments to include the Specialty Sciences segment, which is comprised of assets focused on the treatment of Multiple Sclerosis (Tysabri^®). The majority of corporate expenses, which generally represent shared services, are charged to operating segments as part of a corporate allocation. Unallocated expenses relate to certain corporate services that are not allocated to the segments.

	Three Months Ended							Balance at December 27, 2014
	December 27, 2014
	Net Sales		Operating Income (Loss)			Amortization of Intangibles		Total Assets
Consumer Healthcare	$	529.6	$	74.9		$	8.7	$	6,310.9
Nutritionals	130.6		7.2			7.2		1,057.2
Rx Pharmaceuticals	276.6		109.7			18.0		2,612.9
API	30.0		7.4			0.5		255.2
Specialty Sciences	86.6		9.5			72.8		6,135.6
Other	18.3		1.1			0.4		88.9
Unallocated expenses	—		(25.4		)	—		—
Total	$	1,071.7	$	184.4		$	107.6	$	16,460.7
	Three Months Ended							Balance at December 28, 2013
	December 28, 2013
	Net Sales		Operating Income (Loss)			Amortization of Intangibles		Total Assets
Consumer Healthcare	$	536.3	$	89.5		$	5.3	$	2,345.5
Nutritionals	139.7		13.3			7.4		1,014.0
Rx Pharmaceuticals	246.6		100.4			21.5		1,940.1
API	30.0		8.2			0.5		284.7
Specialty Sciences	7.4		(19.0		)	8.7		8,023.8
Other	19.0		0.6			0.4		104.7
Unallocated expenses	—		(106.4		)	—		—
Total	$	979.0	$	86.6		$	43.8	$	13,712.8

	Six Months Ended
	December 27, 2014
	Net Sales		Operating Income (Loss)			Amortization of Intangibles
Consumer Healthcare	$	1,022.9	$	140.2		$	17.4
Nutritionals	255.8		15.7			14.4
Rx Pharmaceuticals	471.2		174.4			35.0
API	54.8		14.4			1.0
Specialty Sciences	178.4		24.4			145.6
Other	40.0		2.0			0.8
Unallocated expenses	—		(49.6		)	—
Total	$	2,023.1	$	321.5		$	214.2
	Six Months Ended
	December 28, 2013
	Net Sales		Operating Income (Loss)			Amortization of Intangibles
Consumer Healthcare	$	1,074.8	$	179.5		$	10.6
Nutritionals	268.7		21.0			14.7
Rx Pharmaceuticals	450.2		183.5			37.7
API	73.2		30.6			1.0
Specialty Sciences	7.4		(19.0		)	8.7
Other	38.1		1.8			0.9
Unallocated expenses	—		(131.2		)	—
Total	$	1,912.4	$	266.2		$	73.6